Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By



This article was originally published in The Tan Sheet

Executive Summary

PHARMACEUTICAL FORMULATIONS FISCAL 1993 REVENUES JUMP 50% to $ 45.5 mil., the Edison, N. J. generic firm announced Sept. 29. Net income for the twelve-month period ended June 30, 1993 totaled $ 1.7 mil. compared with a loss of $ 2.3 mil. in fiscal 1992, Pharmaceutical Formulations, Inc. (PFI) reported. The company attributed the revenue increase to "the continuous addition of new private-label customers and the expansion of sales of existing and newly developed products to various drug and food chains and mass merchandisers who are already the company's customers." Two factors driving this growth, PFI asserted, are the need for "the most economical products for the consumer" and the "increase [in] consumer acceptance" of private label products. "A growing segment of the company's business, which is expected to contribute even more significantly in the future to PFI's profits, is the contract manufacturing of name-brand products on behalf of the pharmaceutical companies with a major presence in the over-the-counter marketplace," PFI predicted. Formerly known as PharmaControl, PFI said it manufactures and distributes "more than 80 different types of generic OTC solid dosage pharmaceutical products in tablet, caplet, and capsule form . . . sold under its customers' store-brand labels or in bulk form to repackagers and distributors." PFI's product line includes analgesics, antacids, laxatives, antihistamines, and cough-cold preparations. Chart omitted.

You may also be interested in...

People In Brief

Perrigo promotes in pricing, planning

In Brief

Combe sells most of its OTC brands

Supplement GMP Warning Letters Make Modest Debut In 2010

Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts